Please Wait
Applying Filters...
menu
    • menu
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Savolitinib

    DEVELOPMENTS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    HUTCHMED Highlights SACHI Phase III Results in the Lancet
    HUTCHMED Highlights SACHI Phase III Results in the Lancet

    14 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-14/hutchmed-highlights-publication-of-phase-iii-sachi-results-in-the-lancet

    PHARMIWEB
    14 Jan 2026
    Share Share
    Hutchmed's NDA Acceptance in China with Status for Savolitinib
    Hutchmed's NDA Acceptance in China with Status for Savolitinib

    30 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/30/3211274/0/en/HUTCHMED-Announces-NDA-Acceptance-in-China-with-Priority-Review-Status-for-Savolitinib-for-the-treatment-of-Gastric-Cancer-Patients-with-MET-Amplification.html

    GLOBENEWSWIRE
    30 Dec 2025
    Share Share
    Hutchmed Expands Its NRDL Coverage, Joins First Commercial List
    Hutchmed Expands Its NRDL Coverage, Joins First Commercial List

    07 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/08/3201158/0/en/HUTCHMED-Announces-Expanded-Coverage-on-National-Reimbursement-Drug-List-and-Inclusion-in-the-First-Commercial-Insurance-Drug-List-in-China.html

    GLOBENEWSWIRE
    07 Dec 2025
    Share Share
    HUTCHMED Completes Enrollment In SAFFRON Ph III Trial
    HUTCHMED Completes Enrollment In SAFFRON Ph III Trial

    04 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/05/3181024/0/en/HUTCHMED-Announces-Enrollment-Completed-of-SAFFRON-Global-Phase-III-Trial-of-ORPATHYS-and-TAGRISSO-Combination-for-Certain-Lung-Cancer-Patients-with-MET-Overexpression-and-or-Ampli.html

    GLOBENEWSWIRE
    04 Nov 2025
    Share Share
    Hutchmed Showcases Clinical Data At Esmo Congress 2025
    Hutchmed Showcases Clinical Data At Esmo Congress 2025

    01 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/02/3160056/0/en/HUTCHMED-Highlights-Clinical-Data-to-be-Presented-at-the-ESMO-Congress-2025.html

    GLOBENEWSWIRE
    01 Oct 2025
    Share Share
    HUTCHMED Finishes Enrollment for SANOVO Phase III Trial in China
    HUTCHMED Finishes Enrollment for SANOVO Phase III Trial in China

    19 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/20/3136084/0/en/HUTCHMED-Completes-Patient-Enrollment-of-SANOVO-Phase-III-Trial-of-ORPATHYS-and-TAGRISSO-Combination-as-a-First-Line-Therapy-for-Certain-Lung-Cancer-Patients-in-China.html

    GLOBENEWSWIRE
    19 Aug 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.